|
Total n = 35
|
Responder n = 15
|
Non-Responder n = 20
|
Response P value
|
Overall survival P value
|
---|
TMB [Mut/Mb]
|
> 23
|
6
|
6
|
0
|
0.002
1*
|
0.062
|
≤ 23
|
24
|
6
|
18
|
ctDNA [copies/ml] detection5
|
Not detectable
|
14
|
10
|
4
|
0.011
1*
|
0.006
2*
|
Detectable
|
18
|
4
|
14
|
ctDNA [copies/ml] increase5
|
Not increasing
|
20
|
12
|
8
|
0.008
1*
|
0.03
2*
|
Increasing
|
11
|
1
|
10
|
Cell-free DNA [ng/ml]6
|
Decrease > 50%
|
7
|
5
|
2
|
0.022
3*
|
0.005
4*
|
Stable
|
15
|
7
|
8
|
Increase > 50%
|
9
|
1
|
8
|
LDH baseline elevated
|
No
|
21
|
11
|
10
|
0.2961
|
0.001
2*
|
Yes
|
14
|
4
|
10
|
Targeted therapy before
|
No
|
25
|
12
|
13
|
0.4581
|
0.001
2*
|
Yes
|
10
|
3
|
7
|
Sex
|
Male
|
19
|
11
|
8
|
0.0871
|
0.005
2*
|
Female
|
16
|
4
|
12
|
Liver metastasis baseline
|
No
|
25
|
14
|
11
|
0.022
1*
|
0.013
2*
|
Yes
|
10
|
1
|
9
|
PD-L1 Expression
|
≥ 1%
|
10
|
6
|
4
|
0.0801
|
0.7722
|
< 1%
|
11
|
2
|
9
|
- * significant (in bold).
- 1Exact Test of Fisher
- 2Log rank test
- 3Exact Chi-Square Test for Trend (Monte Carlo Simulation)
- 4Log rank test for Trend
- 5ctDNA measured by tumor-specific variant [copies/ml plasma] at first follow-up after start of combined immunotherapy
- 6Cell-free DNA [ng/ml plasma] at first follow-up after start of combined immunotherapy